The maturing of RBM implementation

  As we at TRI continue to engage with industry on RBM implementation, I am pleased with the observations that we are currently making across a range of CRO and Pharma companies. Rolling back the clock 18-24 months and most of the discussions we were having with customers and prospects were about risk detection, data visualisation and stats models….

Read More

Does Risk-based monitoring improve inspection readiness?

This highlights a serious concern in the gap between what the regulatory authorities are looking for from RBM and the way in which RBM is being practiced. Triumph Research Intelligence (TRI) have engaged both the MHRA and FDA during the design and development of their operational platform for quality oversight and RBM, and during those discussions heard loud and…

Read More

2014 Risk-based Monitoring in Clinical Studies

If you want to find out more about Risk-based Monitoring, the opportunity it presents and the approach TRI are taking to helping companies start their RBM journey then please join us at the CBI event. Triumph’s CEO, Duncan Hall will be presenting to the audience on the following topic:   Operationalizing RBM — Turning Insight into Action into Evidence…

Read More